ロード中...
Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types
PURPOSE: The efficacy and safety of regorafenib have been demonstrated in phase 3 trials for multiple tumor types, including metastatic colorectal cancer (mCRC) (CORRECT [NCT01103323]; CONCUR [NCT01584830]), advanced gastrointestinal stromal tumor (GIST) (GRID [NCT01271712]), and hepatocellular carc...
保存先:
| 出版年: | Cancer Manag Res |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8285228/ https://ncbi.nlm.nih.gov/pubmed/34285574 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S305939 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|